The Business Of Biotech Podcast
-
Precision Drug Delivery with Ampersand Biomedicines' Jason Gardner, Ph.D.
4/10/2024
Ampersand Biomedicines CEO Jason Gardner, Ph.D. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with the Flagship Pioneering-backed Ampersand, he's putting all those hard-fought lessons to good use.
-
Funding Alzheimer's Tx Dev with ADDF's Karen Harris
3/31/2024
We've really been looking forward to dropping this episode with Karen Harris, Chief Financial Officer and Head of Mission-Related Investing at the Alzheimer's Drug Discovery Foundation. While the markets have warmed a bit since we recorded this episode, Karen's thoughtful perspective on the sometimes tumultuous Alzheimer's therapeutics space is valuable to any drug developer working in the cognitive medicines arena.
-
The AI Impact with Generate:Biomedicines' Mike Nally
3/24/2024
Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artificial intelligence. One company on the bullish end of the spectrum is Flagship Pioneering's Generate: Biomedicines, which bills itself at the "intersection of machine learning, biological engineering, and medicine."
-
Strategic Deals With CinRx's Gavin Samuels, M.D.
3/17/2024
Gavin Samuels, M.D., found his work as an intensive care physician boring. It wasn't until he left the hospital and entered biopharma that he found his footing. Now, he's Chief Business Officer and General Partner at CinRx Pharma, where a deep pipeline of early- to late-stage candidates keeps him on his dealmaking toes. Dr. Samuels' introspective reflections on biotech dealmaking and negotiations plants this episode firmly on the Business of Biotech podcast highlight reel.
-
Serial Success With Triumvira's Rob Williamson
3/10/2024
Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Learn secrets to his serial success on this week's Business of Biotech podcast.
-
The Innovator's Dilemma with Lumen Bioscience's Brian Finrow, J.D.
3/4/2024
In biotech, when "one of these things doesn't look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is praised and rewarded. On the other, unfamiliarity breeds skepticism from the investment community. Brian Finrow, J.D. embraces that reality and the challenges that come with it.
-
Precision Radiopharmaceuticals with Ratio's Jack Hoppin, Ph.D.
2/21/2024
Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment for players in the space to put on a precision medicine clinic, so to speak. What’s more, Radiopharmaceuticals create a unique business opportunity given the closely related and necessary companion diagnostic arena.
-
Managing Mergers With Sail's Guillaume Pfefer, Ph.D
2/15/2024
You might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger was executed, how the two companies are integrating their talent, IP, and resources, and what Sail Biomedicines CEO Dr. Guillaume Pfefer and team are currently doing to take the fruits of the company’s platform into the clinic.
-
Reprogramming Human Cells With bit.bio's Mark Kotter, M.D.
2/12/2024
The concept of programmable biology is fueling a new breed of biotech, one that requires the marriage of computational and traditional science (and both computational and traditional scientists) on the entire journey from discovery to commercial. Bit.bio is exemplary of this new breed.
-
Inhalable mRNA With Ethris' Carsten Rudolph, Ph.D.
2/1/2024
Without doubt, the grand and collaborative experiment that was the mRNA COVID vaccine contributed mightily to the pandemic response and continues to save lives untold. It also demonstrated the collective power of public/private partnership in biopharma.